Recent report published by MarketsandMarkets forecast that The global market, consisting of devices used in both systemic and blood-borne oncology treatment procedures, was valued at $4.4 billion in 2011 and is expected to reach $5.8 billion by 2016, at a CAGR of 5.3% from 2011 to 2016. Plus
